Kiniksa Pharmaceuticals/$KNSA
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Kiniksa Pharmaceuticals
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Ticker
$KNSA
Sector
Primary listing
Employees
315
Headquarters
Website
KNSA Metrics
BasicAdvanced
$2.9B
82.19
$0.47
0.03
-
Price and volume
Market cap
$2.9B
Beta
0.03
52-week high
$42.05
52-week low
$17.82
Average daily volume
511K
Financial strength
Current ratio
3.848
Quick ratio
3.268
Long term debt to equity
1.312
Total debt to equity
1.815
Profitability
EBITDA (TTM)
39.641
Gross margin (TTM)
52.79%
Net profit margin (TTM)
6.01%
Operating margin (TTM)
6.38%
Effective tax rate (TTM)
26.13%
Revenue per employee (TTM)
$1,900,000
Management effectiveness
Return on assets (TTM)
3.76%
Return on equity (TTM)
7.39%
Valuation
Price to earnings (TTM)
82.192
Price to revenue (TTM)
4.703
Price to book
5.41
Price to tangible book (TTM)
5.57
Price to free cash flow (TTM)
27.641
Free cash flow yield (TTM)
3.62%
Free cash flow per share (TTM)
1.388
Growth
Revenue change (TTM)
55.68%
Earnings per share change (TTM)
-465.19%
3-year revenue growth (CAGR)
50.04%
3-year earnings per share growth (CAGR)
-38.92%
What the Analysts think about KNSA
Analyst ratings (Buy, Hold, Sell) for Kiniksa Pharmaceuticals stock.
Bulls say / Bears say
ARCALYST® net product revenue in Q2 2025 reached $156.8 million, up 52% year-over-year, and Kiniksa raised its full-year ARCALYST sales guidance to $625–$640 million, underscoring robust commercial execution. (GlobeNewswire)
As of June 30, 2025, Kiniksa held $307.8 million in cash, cash equivalents, and short-term investments with no debt, providing ample runway for ongoing operations and pipeline development. (GlobeNewswire)
The company has initiated the Phase 2 dose-focusing portion of its pivotal Phase 2/3 trial of KPL-387 in recurrent pericarditis, advancing its lead pipeline asset toward potential market entry in 2028/2029 and offering a clear growth catalyst beyond ARCALYST. (GlobeNewswire)
Kiniksa’s decision to discontinue development of abiprubart in Sjögren’s disease and terminate the AstraZeneca-licensed mavrilimumab program narrows its pipeline to essentially one late-stage asset, increasing execution risk if KPL-387 encounters setbacks. (Fierce Biotech)
Total operating expenses for Q2 2025 rose to $136.6 million from $108.7 million in Q2 2024, while the company recorded no license or collaboration revenue in Q2 2025 versus $5.2 million a year earlier, putting pressure on margins despite strong product sales. (GlobeNewswire)
KPL-387 Phase 2 dose-focusing data are not expected until the second half of 2026, delaying potential revenue diversification beyond ARCALYST for at least another year, and prolonging dependence on a single product for cash flow. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2025.
KNSA Financial Performance
Revenues and expenses
KNSA Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kiniksa Pharmaceuticals stock?
Kiniksa Pharmaceuticals (KNSA) has a market cap of $2.9B as of November 09, 2025.
What is the P/E ratio for Kiniksa Pharmaceuticals stock?
The price to earnings (P/E) ratio for Kiniksa Pharmaceuticals (KNSA) stock is 82.19 as of November 09, 2025.
Does Kiniksa Pharmaceuticals stock pay dividends?
No, Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders as of November 09, 2025.
When is the next Kiniksa Pharmaceuticals dividend payment date?
Kiniksa Pharmaceuticals (KNSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals (KNSA) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.